Study Title
A Safety/Efficacy Study of SGN-30 (Antibody) in Patients With Refractory or Recurrent CD30+ Hematologic Malignancies (NCT00051597)

Trial Description
The purpose of this study is to evaluate a multi-dose regimen of SGN-30, a novel chimeric monoclonal antibody (mAb), in patients with refractory or recurrent CD30+ hematologic malignancies.

This is a single-arm, open-label phase I/II study designed to define the toxicity profile, pharmacokinetic (PK) profile, and anti-tumor activity of a multi-dose regimen of SGN-30 in patients with refractory or recurrent CD30+ hematologic malignancies. The phase I study will be a modified dose escalation of SGN-30. Based on preclinical pharmacology and toxicokinetics (TK) and the first use in human single-dose phase I study, SGN-30 will be administered on a weekly schedule. An initial dose of 2 mg/kg will escalate until the maximum tolerated dose (MTD) has been reached or until a weekly dose of 12 mg/kg is achieved.

This trial is sponsored by Seattle Genetics. [1]

Study Data

  • Conditions:
    • Hodgkin Disease
    • Lymphoma, Large-Cell
    • Sarcoma, Kaposi
    • Lymphoma, T-Cell, Cutaneous
    • Lymphoma, B-Cell
  • Interventions:
    • Drugs used in this trial
      • SGN-30 (Seattle Genetics)
  • Phase: I & II
  • Estimated Enrollment: 70
  • Start:
  • Completion: August 2003
  • Last verified: October 2011

Study Schematic


Click here to Return to Drug map

Last Editorial review: July 17, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015/ 2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.